Consolidated Balance Sheets (USD $)	Feb. 28, 2015	Aug. 31, 2014
Current Assets:
Cash and cash equivalents	$ 28,941	$ 17,504
Accounts receivable (net of allowance of $71,000 and $9,000)	910,328us-gaap_AccountsAndNotesReceivableNet	213,399us-gaap_AccountsAndNotesReceivableNet
Inventory	137,436us-gaap_InventoryFinishedGoods	31,271us-gaap_InventoryFinishedGoods
Prepaid expenses and other current assets	12,996	9,307
Prepaid commissions and finders' fees	171us-gaap_PrepaidExpenseCurrent	3,152us-gaap_PrepaidExpenseCurrent
Total current assets	1,089,872us-gaap_AssetsCurrent	274,633us-gaap_AssetsCurrent
Property and equipment (net of accumulated depreciation of $34,535 and $28,264)	37,870us-gaap_PropertyPlantAndEquipmentNet	39,967us-gaap_PropertyPlantAndEquipmentNet
Deposits and other assets	58,134us-gaap_DepositAssets	14,582us-gaap_DepositAssets
Goodwill	2,404,389us-gaap_Goodwill	1,781,779us-gaap_Goodwill
Patents, registrations (net of amortization of $101,046 and $97,983)	21,434us-gaap_OtherIntangibleAssetsNet	24,497us-gaap_OtherIntangibleAssetsNet
Total assets	3,611,699us-gaap_Assets	2,135,458us-gaap_Assets
Current liabilities:
Convertible notes payable (net of discount of $223,836 and $99,491)	250,917us-gaap_ConvertibleDebt	436,308us-gaap_ConvertibleDebt
Notes payable (net of discount of $4,656 and $18,596)	2,367,890us-gaap_NotesAndLoansPayableCurrent	946,104us-gaap_NotesAndLoansPayableCurrent
Notes payable - related parties	9,086	51,600
Inventory finance agreements	391,939
Accounts payable and other accrued expenses	1,030,403	732,934
Accrued interest payable	191,970us-gaap_InterestPayableCurrent	148,681us-gaap_InterestPayableCurrent
Accrued interest payable - related parties	7,393us-gaap_DueToRelatedPartiesCurrent	6,342us-gaap_DueToRelatedPartiesCurrent
Current portion of long term debt	95,064us-gaap_LongTermDebtCurrent	82,532us-gaap_LongTermDebtCurrent
Total current liabilities	4,344,662us-gaap_LiabilitiesCurrent	2,404,501us-gaap_LiabilitiesCurrent
Long-term liabilities:
Notes payable (net of current portion)	400,800us-gaap_NotesAndLoansPayable	395,675us-gaap_NotesAndLoansPayable
Convertible notes payable
Total long-term liabilities	400,800us-gaap_LiabilitiesNoncurrent	395,675us-gaap_LiabilitiesNoncurrent
Total liabilities	4,745,462us-gaap_Liabilities	2,800,176us-gaap_Liabilities
Stockholders' Deficit:
Common stock, par value $.001 per share; 750,000,000 shares authorized;; 750,000,000 shares authorized; 209,599,660 and 134,600,152 shares issued and outstanding at February 28, 2015 and August 31, 2014, respectively	209,599us-gaap_CommonStockValue	134,600us-gaap_CommonStockValue
Additional paid-in capital	47,974,911us-gaap_AdditionalPaidInCapital	47,565,869us-gaap_AdditionalPaidInCapital
Accumulated deficit prior to reentering development stage	(49,339,053)	(48,370,395)
Common stock subscribed (4,500,000 and 1,058,201 shares issuable, respectively at February 28, 2015 and August 31, 2014)	20,572us-gaap_CommonStockSharesSubscriptions	5,000us-gaap_CommonStockSharesSubscriptions
Total stockholders' deficit	(1,133,763)us-gaap_StockholdersEquity	(664,718)us-gaap_StockholdersEquity
Total liabilities and stockholders' deficit	3,611,699	2,135,458
Series A Preferred Stock [Member]
Stockholders' Deficit:
Preferred stock	129	129
Series D Preferred Stock [Member]
Stockholders' Deficit:
Preferred stock	$ 79	$ 79

Oncologix Tech Inc. 10-Q